Celltrion announced on the 17th that Herjumma had won the Brazilian federal government’s tender. This marks the seventh consecutive year since the company first secured the contract in 2020. With this contract, Celltrion’s Brazilian subsidiary will be the sole supplier of approximately 1 million vials through the end of next year.
According to the company, this tender accounts for approximately 80% of Brazil’s public-sector trastuzumab market. Herjumma currently maintains the top prescription position in Brazil with a market share of approximately 50%, according to IQVIA. Celltrion expects this supply contract to serve as a foundation for maintaining its existing market share and expanding sales.
The Brazilian pharmaceutical market is divided roughly 80:20 between the public and private sectors. Celltrion’s Brazilian subsidiary has participated in tenders primarily in the larger public sector, building a track record of successful supply. It has also focused on establishing networks with federal government officials and expanding its engagement with key healthcare professionals.
Going forward, the company plans to focus on leveraging the prescription experience gained in the public sector to expand into the private sector. In Brazil, key healthcare professionals often practice in both public and private healthcare institutions; therefore, the company believes that experience with the product in the public sector can lead to increased prescriptions in the private sector.
Celltrion explained that its production capacity to reliably supply large volumes also played a positive role in securing this contract. Given the requirement to supply approximately 1 million vials to a single country, the company noted that supply stability was just as important as price and product competitiveness.
In addition, Celltrion’s Brazilian subsidiary has been actively building networks with key stakeholders in the federal government while steadily expanding its engagement with key healthcare professionals. Given that many key healthcare professionals in Brazil work in both public and private healthcare institutions, the company plans to leverage the product trust and brand preference accumulated in the public sector to drive further growth for Herzuma in the private sector.
The company is also pushing for the market entry of follow-on products. “Omriclo,” a biosimilar of omalizumab launched in Brazil late last year, has secured supply contracts through tenders issued by the Santa Catarina state government and others. According to the company, it has also achieved a market share of approximately 26% in the private sector. Celltrion plans to leverage its advantage as the first omalizumab biosimilar to enter the local market to expand prescriptions.
Preparations are underway for the launch of “Idenzelt” (active ingredient: aflibercept), a treatment for ophthalmic diseases, and “Aptozma” (active ingredient: tocilizumab), a treatment for autoimmune diseases, both targeted for release by the end of this year. In particular, the company plans to expand its business scope in Brazil to include ophthalmic diseases through Idenzelt, while also building networks with relevant medical professionals and institutions and expanding its specialized sales force.
Kang Kyung-doo, Head of Celltrion’s Latin America Region, stated, “Our long-standing success in Brazil is the result of a synergistic combination of sales strategies optimized for the local market, a robust network, and high product reliability.” He added, “By combining the direct-to-market competitiveness we’ve established through our existing products with our upcoming product portfolio, we will expand our market influence in Brazil and use this as a springboard to continue creating new growth opportunities across all of Latin America.”